<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103697</url>
  </required_header>
  <id_info>
    <org_study_id>RuCorT-01</org_study_id>
    <nct_id>NCT04103697</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer</brief_title>
  <acronym>RuCorT-01</acronym>
  <official_title>A Multicenter Prospective Phase III Clinical Trial of Neoadjuvant CapOx Chemotherapy in Patients With Intermediate Risk Middle and Upper Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 4 cycles of neoadjuvant CapOx chemotherapy
      is more effective than the upfront surgery in patients with intermediate risk CRM&quot;-&quot; mid and
      upper rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of neoadjuvant chemotherapy compared to upfront
      surgery in intermediate risk rectal cancer patients. This is a prospective multicenter
      open-label randomized phase III clinical trial. Patients will be randomized using an online
      randomization system to receive either 4 cycles of neoadjuvant CapOx (oxaliplatin 130 mg/m2
      iv day 1, capecitabine 2000 mg/m2 per os bid days 1-14) chemotherapy and surgery or surgery
      alone. A stratification will be performed based on N stage, tumor location in the middle or
      upper rectum and clinical center. Patients with cT3-4aN1-2M0, T4aN0M0 cancer in the upper
      rectum and сТ2-Т3bN1M0 (based on preoperative MRI) cancer in the middle rectum are included.
      All patients are potential candidates for adjuvant chemotherapy, according to preoperative
      staging. Chemoradiotherapy (50 Gy with concomitant capecitabine 825 mg/m2 per os bid on
      radiation days) will be performed for patients with tumor progression after neoadjuvant
      chemotherapy. The decision to proceed with adjuvant chemotherapy postoperatively will be
      based on pTNM stage in both treatment arms, according to actual treatment guidelines. The
      target accrual is 280 patients in each treatment arm (including 10% potential data loss)
      based on potential benefit of 10% 3-yr disease-free survival (75% vs 85%), α=0,05, power 80%
      in the experimental arm. An interim analysis is planned after 50% of the patients will reach
      a 3-year followup. Pelvic Magnetic Resonance Imaging (MRI) is performed in all patients for
      staging before and after neoadjuvant chemotherapy and before surgery. Pelvic MRI isbject to
      central review. Conduction of this study and data collection are controlled by a local
      institutional board.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjuvant chemotherapy compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients who receive a complete course of adjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute chemotherapy toxicity</measure>
    <time_frame>14 weeks</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate (pCR)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Morbidity measured according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant chemotherapy disease progression rate</measure>
    <time_frame>14 weeks</time_frame>
    <description>Proportion of patients with disease progression during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative tumor-associated complications rate</measure>
    <time_frame>14 weeks</time_frame>
    <description>The rate of tumor-associated complications (bowel obastruction, bleeding etc) during neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Rectal Neoplasms Malignant</condition>
  <condition>Rectum Carcinoma</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>4xCapOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 cycles of neoadjuvant CapOx chemotherapy (oxaliplatin 130 mg/m2 iv day 1, capecitabine 2000 mg/m2 bid per os days 1-14 every 3 weeks). In case of partial response or stable disease (based on pelvic MRI) patients proceed to surgery. In case of disease progression patients receive 50 Gy pelvic chemoradiotherapy with capecitabine 825 mg/m2 bid per os on radiation days and then surgery. The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard surgery for rectal cancer with partial or total mesorectal excision (based on exact tumor location and surgeons discretion). The decision to proceed with adjuvant chemotherapy postoperatively will be based on pTNM stage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2, bid, per os, days 1-14, 4 cycles</description>
    <arm_group_label>4xCapOx</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2 iv day 1, 4 cycles</description>
    <arm_group_label>4xCapOx</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>4xCapOx</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor</description>
    <arm_group_label>4xCapOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal cancer surgery</intervention_name>
    <description>Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)</description>
    <arm_group_label>4xCapOx</arm_group_label>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically verified colon rectal adenocarcinoma

          -  cT3-4aN1-2M0 cancer of the upper rectum or сТ2-Т3bN1M0 cancer of the middle rectum
             (based on pelvic MRI)

          -  Tumor more than 2 mm from mesorectal fascia (based on pelvic MRI)

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Haemoglobin (HGB) &gt; 90 g/L

          -  Platelet Count (PLT) &gt; 120x10*9/L

          -  Serum creatinine &lt; 150 µmol/L

          -  Total bilirubin &lt; 25 µmol/L

        Exclusion Criteria:

          -  inability to obtain informed consent

          -  distant metastases

          -  synchronous or metachronous tumors

          -  previous chemotherapy or radiotherapy

          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg

          -  clinically significant neurological disorders

          -  previous neuropathy 2 or higher

          -  current infection or heavy systemic disease

          -  pregnancy, breastfeeding

          -  ulcerative colitis

          -  individual intolerance to treatment components

          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency

          -  participation in other clinical trials

          -  psychiatric disorders, which render patient unable to follow instructions or
             understand his/her condition

          -  technical inability to perform pelvic MRI

          -  inability of long-term followup of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaman Z Mamedli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>N.N.Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator, Consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>mesorectal excision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

